Human Papillomavirus Vaccine and Prevention of Human Papillomavirus-Associated Disease in the USA

  • Lauri E. MarkowitzEmail author
  • Susan Hariri


The introduction of human papillomavirus (HPV) vaccine has ushered a new era in the prevention of a common sexually transmitted infection that can cause cancer and other benign but serious diseases. Even before it first became available, HPV vaccine was anticipated with enthusiasm for cancer prevention, but there was also concern that the vaccine might detract from secondary prevention of HPV-associated cervical cancers through screening or promote risky sexual behavior. Introduction of HPV vaccine has presented policy, programmatic and communication challenges for public health officials and health-care providers and has required collaboration across disciplines not traditionally involved in immunization, including programs responsible for cancer prevention, sexually transmitted infections, and reproductive health. This chapter focuses on the early years of HPV vaccine introduction in the USA and briefly reviews secondary cervical cancer prevention.


Cervical Cancer Cervical Cancer Screening Genital Wart Vaccine Coverage Vaccine Adverse Event Reporting System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Weinstock H, Berman S, Cates Jr W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6–10.PubMedGoogle Scholar
  2. 2.
    Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10:321–2.PubMedGoogle Scholar
  3. 3.
    Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113:2841–54.PubMedGoogle Scholar
  4. 4.
    Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–46.PubMedGoogle Scholar
  5. 5.
    Saraiya M. Burden of Human Papillomavirus–Associated Cancers—United States, 2004–2008. MMWR. 2012; 61;258–61.Google Scholar
  6. 6.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of ­cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedGoogle Scholar
  7. 7.
    Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 Suppl 10:K29–41.PubMedGoogle Scholar
  8. 8.
    Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301.PubMedGoogle Scholar
  9. 9.
    Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer. 2008;113:2892–900.PubMedGoogle Scholar
  10. 10.
    Lacey CJN, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24 Suppl 3:S3/35–41.Google Scholar
  11. 11.
    Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with ­conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111: 167–77.PubMedGoogle Scholar
  12. 12.
    Moyer VA on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;156:880–891.Google Scholar
  13. 13.
    Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516–42.Google Scholar
  14. 14.
    Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010;60:99–119.PubMedGoogle Scholar
  15. 15.
    Downs LS, Smith JS, Scarinci I, Flowers L, Parham G. The disparity of cervical cancer in diverse populations. Gynecol Oncol. 2008;109:S22–30.PubMedGoogle Scholar
  16. 16.
    Fernandez ME, Allen JD, Mistry R, Kahn JA. Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annu Rev Public Health. 2010;31:235–52.PubMedGoogle Scholar
  17. 17.
    Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer. 2008;113:2855–64.PubMedGoogle Scholar
  18. 18.
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56:1–24.PubMedGoogle Scholar
  19. 19.
    CDC. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59:626–9.Google Scholar
  20. 20.
    Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of ­quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009;2:868–78.Google Scholar
  21. 21.
    Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374: 301–14.PubMedGoogle Scholar
  22. 22.
    Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.PubMedGoogle Scholar
  23. 23.
    Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–71.PubMedGoogle Scholar
  24. 24.
    Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135–45.PubMedGoogle Scholar
  25. 25.
    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5:705–19.PubMedGoogle Scholar
  26. 26.
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV Vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365: 1576–85.PubMedGoogle Scholar
  27. 27.
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401–11.PubMedGoogle Scholar
  28. 28.
    Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7–28.PubMedGoogle Scholar
  29. 29.
    Mosher WD, Chandra A. JJ. Sexual behavior and selected health measures: men and women 15–44 years of age, United States, 2002. Adv Data. 2006;362:1–55.Google Scholar
  30. 30.
    Middleman AB. New adolescent vaccination recommendations and how to make them “stick”. Curr Opin Pediatr. 2007;19:411–6.PubMedGoogle Scholar
  31. 31.
    Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan D, Patel SS C, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813–9.PubMedGoogle Scholar
  32. 32.
    Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis. 2009;200:1059–67.PubMedGoogle Scholar
  33. 33.
    Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008;198:e1–11. 261.PubMedGoogle Scholar
  34. 34.
    Schwartz JL. HPV vaccination’s second act: promotion, competition, and compulsion. Am J Public Health. 2010;100:1841–4.PubMedGoogle Scholar
  35. 35.
    Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35.PubMedGoogle Scholar
  36. 36.
    FDA: Gardasil approved to prevent anal cancer. 2010. Accessed at
  37. 37.
    Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co, Inc: Food and Drug Administration. Accessed at
  38. 38.
    CDC. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59: 630–2.Google Scholar
  39. 39.
    Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.PubMedGoogle Scholar
  40. 40.
    Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010;46:S12–9.PubMedGoogle Scholar
  41. 41.
    Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005;97:896–905.PubMedGoogle Scholar
  42. 42.
    Frankowski BL. Sexual orientation and adolescents. Pediatrics. 2004;113:1827–32.PubMedGoogle Scholar
  43. 43.
    CDC. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60:1705–8.Google Scholar
  44. 44.
    Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343–51.PubMedGoogle Scholar
  45. 45.
    Regan DG, Philp DJ, Waters EK. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sex Health. 2010;7:368–75.PubMedGoogle Scholar
  46. 46.
    Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244–51.PubMedGoogle Scholar
  47. 47.
    Goldie SJ, Kohli M, Grima D, et al. Projected ­clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.PubMedGoogle Scholar
  48. 48.
    Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.PubMedGoogle Scholar
  49. 49.
    Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821–32.PubMedGoogle Scholar
  50. 50.
    Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.PubMedGoogle Scholar
  51. 51.
    Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–23.PubMedGoogle Scholar
  52. 52.
    Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E. Age-based programs for vaccination against HPV. Value Health. 2009;12:697–707.PubMedGoogle Scholar
  53. 53.
    Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol. 2008;70:2126–76.PubMedGoogle Scholar
  54. 54.
    Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;26:4513–8.PubMedGoogle Scholar
  55. 55.
    Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858–67.PubMedGoogle Scholar
  56. 56.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–50.PubMedGoogle Scholar
  57. 57.
    Chesson HW. HPV vaccine cost effectiveness. Presentation before the Meeting of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA; June 22, 2011. Accessed at
  58. 58.
    Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845–52.PubMedGoogle Scholar
  59. 59.
    Santoli JM, Rodewald LE, Maes EF, Battaglia MP, Coronado VG. Vaccines for Children program, United States, 1997. Pediatrics. 1999;104:e15.PubMedGoogle Scholar
  60. 60.
    Advisory Committee on Immunization Practices Vaccines for Children Program; vaccines to prevent human papillomaviruses. Accessed at
  61. 61.
    CDC. National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. MMWR. 2010;59:1018–23.Google Scholar
  62. 62.
    CDC. National and state vaccination coverage among adolescents aged 13 through 17 – United States, 2010. MMWR. 2011;60:1117–23.Google Scholar
  63. 63.
    Vaccines & Immunizations. CDC Vaccine Price List. Accessed November 28, 2010, at
  64. 64.
    Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: Survey of US physicians 18 months after licensure. Pediatrics. 2010;126:425–33.PubMedGoogle Scholar
  65. 65.
    Gottlieb SL, Brewer NT, Smith JS, Keating KM, Markowitz LE. Availability of human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45:438–44.PubMedGoogle Scholar
  66. 66.
    Kahn JA, Cooper HP, Vadaparampil ST, et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev. 2009;18:2325–32.PubMedGoogle Scholar
  67. 67.
    Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009;45:453–62.PubMedGoogle Scholar
  68. 68.
    Barnack JL, Reddy DM, Swain C. Predictors of parents’ willingness to vaccinate for human papillomavirus and physicians’ intentions to recommend the vaccine. Womens Health Issues. 2010;20:28–34.PubMedGoogle Scholar
  69. 69.
    Rand CM, Szilagyi PG, Albertin C, Auinger P. Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study. Pediatrics. 2007;120:461–6.PubMedGoogle Scholar
  70. 70.
    Daley MF, Curtis CR, Pyrzanowski J, et al. Adolescent immunization delivery in school-based health centers: a national survey. J Adolesc Health. 2009;45:445–52.PubMedGoogle Scholar
  71. 71.
    Lindley MC, Boyer-Chu L, Fishbein DB, et al. The role of schools in strengthening delivery of new adolescent vaccinations. Pediatrics. 2008;121 Suppl 1:S46–54.PubMedGoogle Scholar
  72. 72.
    Horlick G, Shaw FE, Gorji M, Fishbein DB. Delivering new vaccines to adolescents: the role of school-entry laws. Pediatrics. 2008;121 Suppl 1:S79–84.PubMedGoogle Scholar
  73. 73.
    Schwartz JL, Caplan AL, Faden RR, Sugarman J. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther. 2007;82:760–3.PubMedGoogle Scholar
  74. 74.
    Javitt G, Berkowitz D, Gostin LO. Assessing mandatory HPV vaccination: who should call the shots? J Law Med Ethics. 2008;36:384–95, 214.PubMedGoogle Scholar
  75. 75.
    Udesky L. Push to mandate HPV vaccine triggers backlash in USA. Lancet. 2007;369:979–80.PubMedGoogle Scholar
  76. 76.
    Colgrove J. The ethics and politics of compulsory HPV vaccination. N Eng J Med. 2006;355: 2389–91.Google Scholar
  77. 77.
    Mandates for adolescent immunizations: recommendations from the National Vaccine Advisory Committee. Am J Prev Med 2008;35:145–51.Google Scholar
  78. 78.
    Association of Immunization Managers. Position statement: school and child care immunization requirements. (Accessed at Scholar
  79. 79.
    Political intrigue in Merck’s HPV vaccine push. Accessed at
  80. 80.
    National Conference of State Legislatures. HPV vaccine. Accessed at
  81. 81.
    Omer SB, Pan WKY, Halsey NA, et al. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA. 2006;296:1757–63.PubMedGoogle Scholar
  82. 82.
    Immigration and Nationality Act. Accessed at
  83. 83.
    Hachey KJ, Allen RH, Nothnagle M, Boardman LA. Requiring human papillomavirus vaccine for immigrant women. Obstet Gynecol. 2009;114:1135–9.PubMedGoogle Scholar
  84. 84.
  85. 85.
    Vaccination coverage among adolescents aged 13–17 years—United States, 2007. MMWR 2008;57:1100–3.Google Scholar
  86. 86.
    National, state, and local area vaccination coverage among adolescents aged 13–17 years–United States, 2008. MMWR 2009;58:997–1001.Google Scholar
  87. 87.
    Dempsey AF, Mendez D. Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health. 2010;47:242–8. 8.e1–8.e6.PubMedGoogle Scholar
  88. 88.
    Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010;171: 357–67.PubMedGoogle Scholar
  89. 89.
    Gottlieb SL, Brewer NT, Sternberg MR, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45:430–7.PubMedGoogle Scholar
  90. 90.
    Rand CM, Schaffer SJ, Humiston SG, et al. Patient-provider communication and human papillomavirus vaccine acceptance. Clin Pediatr. 2010;50:106–13.Google Scholar
  91. 91.
    Taylor L, Hariri S, Sternberg M, Dunne E, Markowitz L. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008. Prev Med. 2011;52:398–400.PubMedGoogle Scholar
  92. 92.
    Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med. 2010;38:525–33.PubMedGoogle Scholar
  93. 93.
    Liddon N, Leichliter J, Markowitz L. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012;42:44–52.PubMedGoogle Scholar
  94. 94.
    Anhang Price R, Tiro JA, Saraiya M, Meissner H, Breen N. Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey. Cancer. 2011;117:5560–8.PubMedGoogle Scholar
  95. 95.
    Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009;48:426–31.PubMedGoogle Scholar
  96. 96.
    Judicial Watch. Judicial watch uncovers new fda records detailing ten new deaths & 140 serious adverse events related to Gardasil. (Accessed at
  97. 97.
    Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28:4731–7.PubMedGoogle Scholar
  98. 98.
    Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23:287–94.PubMedGoogle Scholar
  99. 99.
    National Vaccine Information Center. Gardasil and HPV Infection. Accessed at
  100. 100.
    Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–7.PubMedGoogle Scholar
  101. 101.
    Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279–84.PubMedGoogle Scholar
  102. 102.
    Allen JD, Coronado GD, Williams RS, et al. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. Vaccine. 2010;28:4027–37.PubMedGoogle Scholar
  103. 103.
    Bernat DH, Harpin SB, Eisenberg ME, Bearinger LH, Resnick MD. Parental support for the human papillomavirus vaccine. J Adolesc Health. 2009;45:525–7.PubMedGoogle Scholar
  104. 104.
    Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human papillomavirus vaccination series initiation and completion, National Immunization Survey-Teen, 2008–2009 Pediatrics 2011.Google Scholar
  105. 105.
    Fang CY, Coups EJ, Heckman CJ. Behavioral correlates of HPV vaccine acceptability in the 2007 Health Information National Trends Survey (HINTS). Cancer Epidemiol Biomarkers Prev. 2010;19:319–26.PubMedGoogle Scholar
  106. 106.
    Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009;19: 531–8.PubMedGoogle Scholar
  107. 107.
    Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED. Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine. 2009;27: 3945–52.PubMedGoogle Scholar
  108. 108.
    Allen JD, Othus MKD, Shelton RC, et al. Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev. 2010;19:2187–98.PubMedGoogle Scholar
  109. 109.
    Shelton RC, Snavely AC, De Jesus M, Othus MD, Allen JD. HPV Vaccine Decision-Making and Acceptance: Does Religion Play a Role? J Relig Health 2011.Google Scholar
  110. 110.
    Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 2011;38:197–204.PubMedGoogle Scholar
  111. 111.
    Kahn JA, Ding L, Huang B, Zimet GD, Rosenthal SL, Frazier AL. Mothers’ intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics. 2009;123:1439–45.PubMedGoogle Scholar
  112. 112.
    Stokley S, Cohn A, Dorell C, et al. Adolescent vaccination-coverage levels in the United States: 2006–2009. Pediatrics. 2011;128:1078–86.PubMedGoogle Scholar
  113. 113.
    Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010;46:113–23.PubMedGoogle Scholar
  114. 114.
    Allison M, Kempe A. HPV vaccine for males: physicians’ knowledge attitudes and practices In: ACIP meeting October 2010; 2010Google Scholar
  115. 115.
    Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis. 2010;37:197–203.PubMedGoogle Scholar
  116. 116.
    Friedman AL, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav. 2007;34:471–85.PubMedGoogle Scholar
  117. 117.
    Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Education, training, and communication for HPV vaccines. Vaccine. 2006;24 Suppl 3:S3/ 210–8.Google Scholar
  118. 118.
    Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006;118:2280–9.PubMedGoogle Scholar
  119. 119.
    Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev. 2009;18:363–72.PubMedGoogle Scholar
  120. 120.
    Leader AE, Weiner JL, Kelly BJ, Hornik RC, Cappella JN. Effects of information framing on human papillomavirus vaccination. J Womens Health. 2009;18:225–33.Google Scholar
  121. 121.
    CDC. HPV Vaccines. Accessed at
  122. 122.
    Roberts ME, Gerrard M, Reimer R, Gibbons FX. Mother-daughter communication and human papillomavirus vaccine uptake by college students. Pediatrics. 2010;125:982–9.PubMedGoogle Scholar
  123. 123.
    McRee AL. RP, Gottlieb SL, Brewer NT. Mother–Daughter Communication About HPV Vaccine. J Adolesc Health. 2011;48:314–7.PubMedGoogle Scholar
  124. 124.
    Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol. 2009;114:360–4.PubMedGoogle Scholar
  125. 125.
    Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008;26 Suppl 1:A16–23.PubMedGoogle Scholar
  126. 126.
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145–53.PubMedGoogle Scholar
  127. 127.
    Castle PE, Solomon D, Saslow D, Schiffman M. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer. 2008;113:3031–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of STD PreventionCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations